Latest research on dexlansoprazole

TAK-390MR is an investigational for the treatment of acid related disorders.. TAK-390MR employs a new modified release (MR) technology on an enantiomer of lansoprazole.

dexlansoprazole dosage

A randomized, open-label, two-period crossover study compared the pharmacodynamic effects of single-dose dexlansoprazole MR 60 mg and esomeprazole 40 mg on 24-hour intragastric pH in healthy adult subjects. [source, 2015]
Results showed the average 24-hour intragastric pH following a single dose of dexlansoprazole MR was higher compared to a single dose of esomeprazole (58% versus 48%; P=0.0003) The most profound difference was noted in the second half of the day, presumably due to the longer duration of action of dexlansoprazole MR.20 [source, 2015]
Individual study results using more conservative statistical methods, crude rate analysis, demonstrated that esophagitis healing rates for both 60 mg and 90 mg dexlansoprazole MR doses at week 8 were superior to lansoprazole in one study, while 60 mg dexlansoprazole MR was non-inferior, and 90 mg was superior to lansoprazole in the other study. [source, 2015]
A comparative study performed in healthy volunteers to determine the effect of a single dose of dexlansoprazole 60 mg and esomeprazole 40 mg on the mean gastric pH value over 24 h and the percentage of time with pH > 4 has revealed the following statistically significant differences: 4.3 vs. 3.7 (p = 0.003) and 58% vs. 48% (p < 0.001), respectively [25]. [source, 2015]
In one of the trials, involving patients with the non-erosive form of the disease, heartburn was eliminated within 4 weeks in 50% of the patients receiving dexlansoprazole MR at a dose of 60 mg, in 55% of the patients treated with the 30 mg dose, and in 19% of the placebo patients [9]. [source, 2015]
In a 4-week study of 947 patients diagnosed with the non-erosive form of GERD divided into groups receiving the study drug at doses of 30 or 60 mg or placebo, based on patients’ assessment dexlansoprazole 30 mg has provided a statistically significant higher percentage of days without heartburn for 24 h and heartburn-free nights (54.9% and 80.8%, respectively) than the placebo (18.5% and 51.7%, respectively). [source, 2015]
It must be stressed that the same clinical sample was also used for studying dexlansoprazole at a dose of 90 mg, however without confirming any additional benefits [29]. [source, 2015]
The maintenance of the therapeutic effect and the alleviation of symptoms were assessed for dexlansoprazole at doses of 30 and 60 mg, compared to placebo, for a period of 6 months. [source, 2015]
The safety of use of dexlansoprazole at doses of 30, 60 and 90 mg following oral administration has been assessed in clinical trials covering a period of 1 year. [source, 2015]
dexlansoprazole MR (30 mg once daily) is approved in adults in several countries, including the United States, for treatment of symptomatic nonerosive GERD and maintenance of healed EE and relief of heartburn; a dose of 60 mg once daily is approved for healing EE. [source, 2014]